ABV101

**ABV101** is an investigational fixed-ratio coformulation of insulin and glucagon developed by Abvance Therapeutics for insulin-requiring diabetes. It is designed to preserve insulin-mediated postprandial glucose lowering while using glucagon's counterregulatory glucose-raising activity as a safety net against hypoglycemia. The program originated from research at Vanderbilt University and has supporting human proof-of-concept data from a mealtime study in people with type 1 diabetes; Abvance describes the asset as positioned for further clinical development. ([abvancetherapeutics.com](https://abvancetherapeutics.com/))